Abstract 215P
Background
mnccRCC had a poor response to VEGF-targeted tyrosine kinase inhibitors (TKIs) and the first-line therapy was still limited. Our real-world study aimed to evaluate the effectiveness of tislelizumab-axitinib combination therapy versus TKI monotherapy as the first-line regimen in patients (pts) with mnccRCC.
Methods
Pts with mnccRCC received first-line therapy were identified between Jul. 2019 and Dec. 2022 in Sun Yat-sen University Cancer Center. Pts received first-line TKI monotherapy (TKI group, mainly sunitinib) or tislelizumab plus axitinib therapy (T+A group). Baseline characteristics, objective response rate (ORR), progression-free survival (PFS), PFS2 (defined as time from initial treatment to progression after first subsequent therapy or any-cause death.) and overall survival (OS) were retrospectively collected. The differences on effectiveness between the two groups were compared.
Results
Totally 39 pts were included, with a median age of 46 (17-72) years. 77.1% had an IMDC intermediate/poor-risk disease. 53.8% had papillary RCC, 19.5% had Mit family translocation RCC, 12.1% had chromophobe RCC and others had unclassified RCC. The median follow-up was 23.7 (18.5-29.0) months. The T+A group (n=20) had a significantly longer PFS compared with the TKI group(n=19) (median PFS (95% CI): 11.0 (8.1-14.0) vs 4.6 (3.0-6.2) months, P<0.001). Similarly, ORR was remarkably improved in the T+A group (40.0% vs 10.5%, P=0.006). The PFS2 did not come to the significant difference between the T+A group and TKI group (median PFS2 (95% CI): 18.6 (NR-NR) vs 12.0 (7.9-16.2) months, P=0.646). Median OS was not reached for T+A group and TKI group (median OS (95% CI): NR vs 39.6 (NR-NR) months, P= 0.176).
Conclusions
Tislelizumab plus axitinib could be an effective first-line regimen option for mnccRCC pts.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Sun Yat-sen University Cancer Center.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
362P - Efficacy and safety of MCLA-129, an anti-EGFR/c-MET bispecific antibody, in head and neck squamous cell cancer (HNSCC)
Presenter: Irene Braña
Session: Poster Display
Resources:
Abstract
363P - Effect of financial distress and mental well-being of patients with early vs advanced oral cancer on informal caregiver's quality of life: A prospective real-world data from public health sector hospital
Presenter: Abhinav Thaduri
Session: Poster Display
Resources:
Abstract
364P - Artificial intelligence provides more accurately neck lymph nodes auto-segmentation in radiotherapy
Presenter: chiencheh Chen
Session: Poster Display
Resources:
Abstract
365P - Radiotherapy treatment outcomes and treatment compliance of nasopharyngeal cancer patients in Sabah: A retrospective analysis
Presenter: Anbarasan Anbazagan
Session: Poster Display
Resources:
Abstract
366P - Pre-treatment oral fungal microbiome and nasopharyngeal carcinoma prognosis: A population-based cohort study in southern China
Presenter: Yufeng Chen
Session: Poster Display
Resources:
Abstract
367P - Prevalence and association of sarcopenia with mortality in patients with head and neck cancer: A meta-analysis
Presenter: Claire Lim
Session: Poster Display
Resources:
Abstract
368P - Distinct gene expression profiling explored using nanostring tumor signalling 360 panel with validations in different clinical stages of oral submucous fibrosis patients: A first Indian study
Presenter: Yasasve Madhavan
Session: Poster Display
Resources:
Abstract
370P - Low-dose nivolumab with induction chemotherapy for inoperable HNSCC in 111 patients: Response rates, survival, and implications for LMICs
Presenter: Josh Thomas Georgy
Session: Poster Display
Resources:
Abstract
371P - The role of FDG-PET/CT in the assessment of response to radiation therapy in head and neck cancers: A systematic review and meta-analysis
Presenter: Felix Wijovi
Session: Poster Display
Resources:
Abstract
372P - Effectiveness of HAN-MI-RADS (head and neck molecular imaging-reporting and data system) criterion in head and neck squamous cell carcinoma post concurrent chemoradiotherapy
Presenter: Manoj Gupta
Session: Poster Display
Resources:
Abstract